| ACE-HIGH |
Active Cancer Patients Having Cancer-Related Invasive Procedures or Surgery and Needing Perioperative Management of Anticoagulation Therapy [ACE-HIGH] – A Prospective Management Cohort Study |
Start-up |
Prospective management cohort study evaluating contemporary perioperative anticoagulation management strategies in patients taking DOAC, LMWH or warfarin and requiring biopsy or cancer-related surgery |
|
|
| ADJUST-DVT |
Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study (ADJUST-DVT) |
Completed |
Prospective international cohort study to validate an age-adjusted D-dimer cut-off to rule out DVT |
NCT02384135 |
Results: JAMA 2026 |
| AIRPORT-MPN Pilot |
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN) |
Completed |
Pilot RCT assessing feasibility of a trial of thromboprophylaxis with apixaban in patients with polycythemia vera and JAK2-positive essential thrombocythemia |
NCT04243122 |
Results: Blood 2023 |
| AIRPORT-MPN |
Low-dose direct oral anticoagulant compared to aspirin for the thromboprophylaxis of patients with JAK2-positive myeloproliferative neoplasms |
Start-up |
Full-scale international RCT to compare low-dose thromboprophylaxis with apixaban to ASA in patients with polycythemia vera and JAK2-positive essential thrombocythemia |
|
|
| APPLE |
Assessing the Feasibility of a Randomized Controlled Trial Evaluating Low-Molecular-Weight-Heparin and Aspirin Versus Aspirin Alone in Women with Antiphospholipid syndrome and Pregnancy Loss (APPLE) |
Completed |
Multicentre pilot RCT to assess feasibility of antepartum prophylaxis with LMWH and ASA versus ASA alone in women with APS and past pregnancy loss |
NCT03100123 |
Results: Thrombosis Research 2020 |
| ATTACC |
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) |
Completed |
Prospective, open-label, multicentre, Bayesian adaptive RCT to establish whether therapeutic-dose parenteral anticoagulation improves outcomes for patients hospitalized with COVID-19 |
NCT04372589 |
Results: NEJM 2021 |
| ATTACC-CAP |
Anti-Thrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (ATTACC-CAP) |
Active |
International phase III, open-label, stratified RCT with
Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia |
NCT05848713 |
|
| CAN-CATCH |
Development of risk assessment models for recurrent venous thromboembolism and treatment-related clinically relevant bleeding in patients with cancer-associated thrombosis |
Active |
Prospective cohort study in patients with cancer-associated VTE to develop risk assessment models (RAMs) to predict both recurrent VTE and treatment-related clinically relevant bleeding |
NCT06894576 |
|
| CoAPS |
A prospective study evaluating complement activation among pregnant patients with obstetrical antiphospholipid syndrome |
Active |
Multicentre prospective cohort study to evaluate complement activation during pregnancy in women with APS and healthy controls, using the mHam test, complement studies, and genetic testing to identify treatment targets and risk factors for obstetrical complications |
|
|
| COBRRA |
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRA) |
Completed |
Open-label international RCT comparing bleeding risk with rivaroxaban versus apixaban for acute treatment of VTE |
NCT03266783 |
Abstract: RPTH 2025 |
| COBRRA Pilot |
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban (COBRRA Pilot) |
Completed |
Pilot RCT to assess feasibility of comparing bleeding risk with rivaroxaban versus apixaban for acute treatment of VTE |
NCT02559856 |
|
| COBRRA-AF |
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation (COBRRA AF) |
Active |
Open-label RCT comparing bleeding risk with rivaroxaban versus apixaban in patients with atrial fibrillation |
NCT04642430 |
|
| CONQUER-DVT Pilot |
Colchicine To Quench The Inflammatory Response After Deep Vein Thrombosis: : A Randomized Controlled Pilot Trial |
Active |
Double-blind, placebo-controlled pilot RCT to assess the feasibility of a trial evaluating low-dose colchicine vs. placebo for PTS prevention in patients with first unprovoked DVT |
NCT06440694 |
|
| DVTest |
Deep Vein Thrombosis Testing in the Emergency Department (the DVTest study) |
Start-up |
Prospective validation study evaluating application of the 2day clinical decision rule by emergency physicians |
|
|
| EMPET |
Canadian emergency department-oriented pulmonary embolism testing |
Active |
Prospective study to validate Adjust-Unlikely as a bedside rule-out tool for PE in emergency department patients tested for PE |
NCT06320236 |
|
| EPCAT III |
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty |
Active |
Multicentre RCT evaluating extended VTE prophylaxis comparing rivaroxaban and aspirin to aspirin alone following total hip and knee arthroplasty |
NCT04075240 |
|
| HIP PRO Pilot |
HIP fracture thromboPROphylaxis (HIP PRO) Pilot: A Pilot Randomized Controlled Trial |
Active |
Pilot RCT to evaluate the feasibility of a full-scale trial comparing the safety and efficacy of rivaroxaban versus acetylsalicylic acid (ASA) for thromboprophylaxis after hip fracture surgery |
NCT05775965 |
|
| HIPSTER Pilot |
Rivaroxaban Versus Low Molecular Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Hip Fracture Surgery: a Pilot Randomized Trial |
Start-up |
Pilot RCT to evaluate feasibility of a full-scale trial randomizing patients undergoing hip fracture surgery to receive rivaroxaban or dalteparin for 30 days to prevent VTE |
NCT07228663 |
|
| HIT Pilot |
Optimizing the Diagnosis of Heparin Induced Thrombocytopenia Using Quantified Anti-Platelet Factor 4 Immunological Testing: A Pilot Multicentre Cohort Study (HIT) |
Active |
Prospective cohort study exploring the safety of a novel diagnostic approach to HIT using a combination of pretest probability assessment and quantitative interpretation of the anti-platelet factor 4 immunological assay (anti-PF4). |
NCT03148912 |
|
| LeAD |
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer (LEaD) |
Completed |
Prospective cohort study using the LEFt clinical decision rule and D-dimer for DVT diagnosis in pregnant women who present with signs and symptoms of DVT |
NCT02507180 |
|
| MBD |
Hypercoagulability in patients with metastatic bone disease as determined by Thrombelastography: A prospective pilot study |
Active |
Prospective cohort study of metastatic bone disease patients requiring surgery for acute or impending pathologic fractures, who will undergo serial TEG, platelet PMD, coagulation and inflammatory markers, proteomics analysis and surveillance lower extremity venous ultrasound. |
|
|
| MUFFIN PTS |
The MUFFIN-PTS Trial: Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome |
Completed |
RCT evaluating venoactive medication (6-month course of oral Micronized Purified Flavonoid Fraction (MPFF 1000 mg daily) vs placebo for reduction in PTS |
NCT03833024 |
|
| PANTHER-GI |
Post-Bleed Management of Antithrombotic Therapy after Gastrointestinal Bleeding (PANTHER-GI): A Mixed-Methods Study of Patient Values and Preferences |
Active |
Study on patient values and preferences after OAC-related GI bleeding, using validated methods and collaboration with CanVECTOR patient partners to uphold patient-oriented research principles |
NCT05290857 |
|
| PARTUM |
A randomized controlled trial evaluating aspirin versus placebo in postpartum individuals at risk of venous thromboembolism (The PARTUM Trial) |
Start-up |
International RCT evaluating low-dose aspirin vs. LMWH in postpartum women at risk of developing VTE |
NCT06494878 |
|
| PARTUM Pilot |
Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PARTUM) |
Completed |
Pilot RCT assessing the feasibility of an RCT evaluating aspirin in postpartum women at risk of developing VTE |
NCT04153760 |
Abstract: Lancet Hematology 2025 |
| PAUSE ER |
Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry (PAUSE-ER) |
Completed |
Prospective cohort study assessing clinical outcomes and health resource utilization in DOAC- and VKA-treated patients who require an emergency or urgent surgery/procedure |
NCT04195113 |
|
| PAUSE-2 |
Perioperative Anticoagulant Use for Surgery Evaluation |
Active |
RCT comparing ASRA-based vs. PAUSE-based perioperative DOAC management in AF patients undergoing high-bleed-risk surgery or neuraxial anesthesia |
NCT06957366 |
|
| PAUSE-Virtual |
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual) |
Active |
Prospective cohort study (non-RCT) evaluating the safety and feasibility of replacing in-person pre-surgery visits with virtual consultations for patients on anticoagulants who require an elective surgery/procedure |
NCT06844227 |
|
| PEITHO-3 |
A Reduced Dose of Thrombolytic Treatment for Patients with Intermediate to High-Risk Acute PE (PEITHO-3) |
Active |
International RCT evaluating a reduced dose of thrombolytic treatment for patients with intermediate to high risk acute PE |
NCT04430569 |
|
| PLATO Pilot |
Tumour-Educated Platelets to Detect Cancer in Patients with Unprovoked Venous Thromboembolism: A Pilot Study (PLATO) |
Completed |
Multi-national, prospective, observational cohort study to
evaluate the diagnostic accuracy of platelet mRNA sequencing for occult cancer in the setting of unprovoked VTE |
NCT02739867 |
Results: JTH 2024 |
| PREP & GO |
A prospective cohort study evaluating peripartum anticoagulation management among pregnant women with VTE and its impact on patient outcomes |
Active |
International prospective cohort study of pregnant individuals on anticoagulation for VTE, assessing postpartum bleeding, VTE risk, delivery outcomes, and health care utilization |
NCT05756244 |
|
| PREVENT-GU |
Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial |
Active |
Double-blind RCT to investigate the use of anticoagulants for VTE
prophylaxis in genito-urinary (GU) cancer patients receiving
systemic therapy, such as chemotherapy or immunotherapy |
NCT05920343 |
|
| RADIANT |
Reducing Gastrointestinal Bleeding with Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism (RADIANT) Pilot Randomized Trial |
Active |
Pilot RCT to evaluate feasibility of a trial assessing if omeprazole reduces gastrointestinal bleeding for patients starting anticoagulant therapy for VTE |
NCT06393868 |
|
| RIVASVT-100 Pilot |
Treatment of Portal, Mesenteric, and Splanchnic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study (RIVASVT-100) |
Completed |
Prospective pilot cohort study investigating treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban |
NCT02627053 |
Results: Blood Advances 2022 |
| SAVER |
StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial) |
Active |
International placebo-controlled RCT of rosuvastatin to prevent recurrent VTE |
NCT04319627 |
|
| SLE-CALCULATOR |
SLE-CALCULATOR: Systemic Lupus Erythematosus CArdiovascuLar Disease Event Risk PrediCtion Using Machine LeArning Techniques and NOvel ThRombotic Autoantibodies |
Completed |
Developed the first externally validated online prediction tool for CVD risk in SLE patients, using traditional statistical and machine learning techniques to enhance targeted preventative care |
|
Qualitative results: Women's Health 2025 |
| SOME 2 |
Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism (MVTEP2/SOME2) |
Active |
International RCT of PET scan vs limited screening for occult malignancy in patients with unprovoked VTE |
NCT04304651 |
|
| START Pilot |
START pilot randomized controlled trial (STrategies for Anticoagulation in patients with thRombocytopenia and cancer associated Thrombosis) |
Active |
Multi-centre pilot RCT comparing modified dose LMWH or full-dose LMWH with
platelet transfusion support in patients with thrombocytopenia and CAT |
NCT05255003 |
|
| STOP PPES |
Sodium-glucose cotransporter 2 inhibitor for patients with post-pulmonary embolism syndrome: a pilot study (STOP PPES) |
Start-up |
Pilot RCT is to determine the feasibility of a full-scale trial aiming to evaluate the effects of SGLT2i on exercise capacity in patients with persistent exercise intolerance after PE |
|
|
| STREAM-Line |
Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: A prospective cohort study |
Active |
Multi-centre prospective management cohort study to evaluate a management strategy after the initial 3 months of standard therapeutic anticoagulation for patients
with cancer and catheter-related upper extremity DVT. |
NCT06603870 |
|
| T-REX HMB Pilot |
TRanEXamic acid to decrease Heavy Menstrual Bleeding in individuals anticoagulated for venousthromboembolism (T-REX HMB) Pilot Study |
Start-up |
Pilot RCT to assess the feasibility of a full RCT comparing tranexamic acid (TXA) to placebo in decreasing heavy menstrual bleeding in pre-menopausal individuals anticoagulated for VTE. |
NCT06452342 |
|
| Timely Hip Fracture Care Pathway |
Timely Hip Fracture Care Pathway Implementation: A Feasibility Study |
Active |
Prospective cohort study of a hip fracture care collaborative protocol with patients ≥50 years with a hip fracture that requires urgent surgical intervention receiving pre-injury oral anticoagulants |
|
|
| TILE |
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome (TILE) |
Completed |
Pilot RCT comparing 3-weeks of tinzaparin then DOAC vs DOAC alone for prevention of PTS in high-risk symptomatic DVT patients (Iliac vein or common femoral vein). |
NCT04794569 |
Protocol: BMJ Open 2022 |
| TRIM-Line |
Primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters: TRIM-Line. |
Active |
Multicentre RCT investigating primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters |
NCT05029063 |
|
| TRIM-Line Pilot |
A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Investigating Primary Thromboprophylaxis with Rivaroxaban in Patients with Malignancy and Central Venous Catheters (TRIM-Line) |
Completed |
Pilot RCT to assess the feasibility of a full RCT investigating primary thromboprophylaxis with rivaroxaban in patients
with malignancy and central venous catheters |
NCT03506815 |
Results: RPTH 2021 |
| VVIRTUOSO |
Venous Thrombosis Virtual Surveillance in COVID (VVIRTUOSO) |
Completed |
Prospective cohort study of incidence of VTE after hospitalization for COVID-19 |
|
|
| WAVe |
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism (WAVe) |
Completed |
Prospective cohort study assessing the use of weight-adjusted dalteparin in patients over 90 kg with acute cancer-associated venous thromboembolism |
NCT03297359 |
Results: Am J Hematol. 2026 |
